April 27 Quick Takes: Avalyn raises $35M for fibrosis therapies, plus Actym, LifeSprout, HebeCell, Compass, Immunomic
Fibrosis company Avalyn raises $35.5M series B
Seattle’s Avalyn Pharma Inc. closed a $35.5 million B round, adding to its $62 million series A in 2017. The round was led by Norwest Venture Partners with participation from new investor Pivotal bioVenture Partners and existing investors F-Prime Capital Partners, Novo Holdings A/S, RiverVest Venture Partners and TPG Biotech. The company will use the funds to support a phase II/III trial of AP01 in chronic lung allograft dysfunction (CLAD).
Actym completes $34M A round for immunotherapies
Immuno-oncology play Actym Therapeutics Inc. raised $34 million in a series A led by Boehringer Ingelheim Venture Fund (BIVF) and Panacea Venture, with participation from Illumina Ventures, Korea Investment Partners (KIP) and JLo Ventures. The Berkeley, Calif., company’s Salmonella typhimurium Attenuated Cancer Therapy (STACT) platform delivers directly to tumor-resident immune cells immunomodulatory payloads associated with systemic toxicities when delivered intravenously...